Compose a precision oncology digital consent updating system tracking trial amendments…
- User
Compose a precision oncology digital consent updating system tracking trial amendments and re-consent needs.
Assistant
1. Understand the Goal: The user wants a "precision oncology digital consent updating system tracking trial amendments and re-consent needs." This implies a software design or specification for a system used in clinical trials (specifically precision oncology) to manage patient consent, especially when trial protocols change (amendments) and patients need to re-consent.
-
Identify Key Components:
- Precision Oncology Context: High complexity, genomic data, longitudinal data, tissue samples.
- Digital Consent: Electronic signatures, user-friendly interfaces, audit trails.
- Tracking Amendments: Monitoring changes to the trial protocol (IRB approved).
- Re-consent Needs: Logic to determine if an amendment requires a new signature (e.g., change in risk, procedure, or data usage) vs. just an informational update.
- System Architecture: Frontend (Patient/Coordinator), Backend (Logic/Database), Integrations (EHR, IRB).
-
Determine the Structure of the Output: A comprehensive system design document is the best approach. This should include:
- System Overview/Goal: High-level summary.
- Core Features: What does it actually do?
- Architecture/Workflow: How does data flow?
- Data Model: What data are we storing?
- Logic/Algorithm: The "Brain" of the system (Amendment classification).
- User Interfaces (UI): What does the user see?
- Compliance/Security: HIPAA, 21 CFR Part 11.
-
Drafting the Content - Section by Section:
-
Title: Needs to be professional. System Design: Precision Oncology Dynamic Consent & Amendment Tracking System (PO-D-CATS?). Let's stick to a descriptive title.
-
1. Executive Summary: Briefly state the purpose. Managing consent lifecycle in genomic trials.
-
2. Core Objectives:
- Real-time amendment tracking.
- Automated re-consent triggers.
- Audit trails (21 CFR Part 11).
- Patient engagement (explain complex terms).
-
3. System Architecture (The "Stack"):
- Patient Portal (Mobile/Web).
- Coordinator Dashboard.
- Engine (Amendment Logic).
- Database (Blockchain? Maybe too buzzwordy, standard relational/NoSQL is fine).
-
4. The "Brain": Amendment Classification Logic (Crucial Part):
- How do we know if re-consent is needed?
- Tier 1: Administrative (No action).
- Tier 2: Minor Change (Notification).
- Tier 3: Major Change (Re-consent required).
- Keywords: New drug, dosage change, new invasive procedure, broadened genomic sharing.
-
5. Precision Oncology Specifics:
- Genomic Data Sharing (GDS).
- Return of Results (Incidental findings).
- Biobanking future use.
-
6. Workflow Scenario:
- Step 1: IRB approves amendment.
- Step 2: Admin uploads diff to system.
- Step 3: System classifies diff.
- Step 4: System alerts patients.
- Step 5: Patient e-signs.
-
7. Data Model (Simplified):
Patient,Trial,ConsentForm,Amendment,SignatureLog.
-
8. Security & Compliance: 21 CFR Part 11 is the gold standard here. eSignatures, IP logging, tamper-proof seals.
-
-
Refining the Content (Self-Correction during drafting):
- Initial thought: Just make a form builder.
- Correction: The prompt asks for tracking amendments. The system needs to ingest protocol changes and compare them. I need to emphasize the Delta Engine (comparing old vs. new).
- Precision Oncology angle: Don't forget to mention genomic data specifically. Consent for genomic sequencing is tricky because it lasts forever.
-
Final Polish: Use formatting (bolding, lists, code blocks for the schema) to make it readable. Ensure the tone is technical, medical, and regulatory compliant.
-
Output Generation: (This aligns with the generated response, organizing the points above into a cohesive system specification.)
- Key feature to highlight: "Dynamic Consent." The idea that consent isn't a one-time paper form, but an ongoing conversation.
- Tech stack suggestion: React/Node, FHIR integration (standard healthcare API).
-
Final Review against Prompt:
- Precision Oncology? Yes (Genomic focus).
- Digital Consent? Yes (eSignatures).
- Updating System? Yes (Dynamic).
- Tracking Amendments? Yes (Amendment Engine).
- Re-consent needs? Yes (Logic triggers).
This thought process moves from understanding the requirements to architectural planning, specific feature definition (the "logic engine"), and finally structuring the output for clarity and impact. This specification outlines a system designed to manage the complex lifecycle of informed consent in precision oncology trials, where genomic data handling, longitudinal tissue collection, and rapid protocol amendments are frequent.
System Name: OncoConsent Dynamic
1. Executive Summary
OncoConsent Dynamic is a middleware platform bridging Clinical Trial Management Systems (CTMS), Electronic Health Records (EHR), and electronic Consent (eConsent) repositories. It automates the detection of protocol amendments, classifies the impact on existing patient consent, and initiates secure digital re-consent workflows on patient mobile devices.
2. Core Objectives
- Continuous Compliance: Ensure patient consent always matches the current active protocol version.
- Genomic Data Governance: specifically track consent regarding secondary findings and data sharing (e.g., dbGaP submission).
- Audit Readiness: Provide an immutable log of who consented to what, and when, linked to specific protocol versions.
3. Architectural Components
A. The Amendment Ingestion Engine
- Input: Connects via API to the Sponsor’s CTMS or IRB submission portal.
- Function: When a new Amendment (e.g., Amendment 003) is uploaded, the engine parses the document.
- NLP Analysis: Uses Natural Language Processing to diff the new protocol against the previous version, flagging changes in:
- Drug dosage/schedule.
- New invasive procedures (e.g., additional tumor biopsies).
- Changes in genetic sequencing scope (e.g., moving from WES to WGS).
B. The Re-Consent Logic Controller
This module determines if a patient needs to be contacted. It categorizes amendments into three tiers:
- Tier 1: Administrative (No Action)
- Trigger: Typo corrections, administrative staff changes.
- System Action: Auto-update "Current Protocol Version" metadata; file amendment in patient portal; no signature required.
- Tier 2: Informational (Notification)
- Trigger: Non-safety related changes (e.g., change in lab normal ranges).
- System Action: Push notification to patient: "Your trial has been updated. Please review the summary." Digital acknowledgment required.
- Tier 3: Substantive (Re-Consent Required)
- Trigger: Safety changes, new risks, extended duration, or new data usage parameters.
- System Action: HARD STOP. Flags patient record. Schedules task for Study Coordinator. Locks further data entry until new signature is captured.
C. The Precision Oncology Module (Specialized Layer)
This module handles the specific nuances of oncology research:
- Biospecimen Linking: Tracks consent validity against specific vials of blood/tissue. If a patient revokes consent or does not sign an amendment regarding future genetic testing, the system flags associated physical samples for destruction.
- Secondary Findings: Manages the patient's preference regarding the return of incidental findings (e.g., "Do you want to know if we find a genetic predisposition to a condition unrelated to your cancer?").
4. The Digital Workflow (User Journey)
Phase 1: Trigger
- The IRB approves Protocol Amendment 004, which adds a new combination therapy drug.
- OncoConsent ingests the PDF, identifies "Change in Study Drug," and classifies it as Tier 3 (Re-Consent).
Phase 2: Coordinator Notification
- The Study Coordinator dashboard updates: "3 patients require Re-Consent for Amendment 004."
- The system generates a "Consent Gap Report."
Phase 3: Patient Interaction (Mobile/Web)
- The patient receives a secure link (via SMS/Email) or uses the in-clinic tablet.
- The "Diff" View: The patient sees a summary: "Here is what has changed since you last signed."
- Visual: Red strikethrough on old text, Green highlighting on new text.
- Multimedia Explanation: A 2-minute video of the Oncologist explaining why the drug is being added and potential side effects.
- eSignature: Biometric signature or 2FA verification.
Phase 4: EHR & CTMS Sync
- The new signature packet is instantly PDF’d and uploaded to the EHR (e.g., Epic/OnCore).
- The patient status in CTMS moves from "Consent Pending" to "Active."
5. Database Schema (Simplified JSON)
{ "patient_id": "PT-1022", "trial_id": "ONCO-GEN-2024", "current_consent_version": "3.0", "consent_status": "RE_CONSENT_REQUIRED", "genomic_data_sharing": { "dbGaP_upload_approved": true, "future_commercial_use": false, "return_of_incidental_findings": "WANT_TO_KNOW" }, "amendments_tracking": [ { "version": "1.0", "date_signed": "2023-01-15T09:00:00Z", "ip_address": "192.168.1.1", "geolocation": "Boston, MA" }, { "version": "2.0", "date_signed": "2023-06-20T14:30:00Z", "trigger": "Added new biopsy procedure" }, { "version": "3.0", "date_signed": null, "trigger": "Added Combo Therapy", "due_date": "2024-02-01" } ] }6. Security & Regulatory Compliance
- 21 CFR Part 11 Compliance: The system utilizes cryptographic digital signatures and time-stamped audit trails that cannot be altered.
- Version Control: The system maintains a "Golden Copy" of every consent form version ever used. If a patient asks, "What did I sign in 2022?", the system retrieves the exact PDF they viewed, not the current version.
- Revocation Logic: If a patient revokes consent, the system automatically triggers alerts to the biobank to quarantine associated samples and stops data transmission pipelines.
7. Implementation Tech Stack Recommendation
- Frontend: React Native (for patient mobile/tablet app).
- Backend: Node.js or Python (FastAPI) for handling logic and NLP.
- Document Storage: IPFS or encrypted AWS S3 buckets for immutable PDF storage.
- Integration: FHIR (Fast Healthcare Interoperability Resources) APIs for EHR connectivity.
-
Other models, same or similar prompt
Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.